Changeflow GovPing Healthcare Evaluation Method and Device for Comparing Anti...
Routine Rule Added Final

Evaluation Method and Device for Comparing Anti-Anxiety Medicine Effects, EP2024168475A1

Favicon for changeflow.com EPO Patent Bulletin - Health Informatics (G16H)
Published
Detected
Email

Summary

The European Patent Office published patent application EP2024168475A1 covering an evaluation method and device for comparing anti-anxiety medicine effects with efficiency. The patent is classified under G16H 50/70 (healthcare informatics for diagnosis) and designates all EPO contracting states including AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, NL, NO, PL, PT, SE, and others. The invention provides a systematic method for pharmaceutical researchers to assess and compare the efficacy of different anxiety treatments.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published patent EP2024168475A1, granting exclusive rights to an evaluation method and device for comparing anti-anxiety medicine effects with efficiency. The patent classifies under G16H 50/70 and designates all 39 EPO contracting states. The invention enables systematic comparison of efficacy across different anxiety medications.

Pharmaceutical companies and healthcare researchers developing or evaluating anxiety treatments should review the patent claims to assess potential licensing requirements or freedom-to-operate implications for comparable treatment evaluation methods.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

EVALUATION METHOD AND DEVICE FOR COMPARING ANTI-ANXIETY EFFECTS OF DIFFERENT MEDICINES WITH EFFICIENCY

Publication EP2024168475A1 Kind: A1 Apr 08, 2026

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

G16H 50/70 20180101AFI20240823BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Health Informatics (G16H)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP2024168475A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Health Informatics (G16H) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!